Nkarta (NKTX)
(Delayed Data from NSDQ)
$6.40 USD
-0.40 (-5.88%)
Updated May 8, 2024 04:00 PM ET
After-Market: $6.39 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NKTX 6.40 -0.40(-5.88%)
Will NKTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTX
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
NKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
Should You Buy Nkarta (NKTX) Ahead of Earnings?
Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know
Other News for NKTX
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street’s Radar
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Amgen’s Blincyto data send Cullinan higher
Commit To Purchase Nkarta At $5, Earn 31.3% Annualized Using Options
12 Health Care Stocks Moving In Friday's Pre-Market Session